Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articles
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A large WHO pharmacovigilance analysis reveals which myeloma drugs most strongly signal autonomic, motor, and sensory nerve damage.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
Fibrotic tissue stiffness activates a cascade that recruits immune cells and generates DNA-damaging aldehydes, linking dense breast tissue to cancer risk.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
New research shows that the level of RAS oncogene activity determines whether cells become senescent or tumorigenic — a key cancer-prevention insight.
Plongez au cœur des mécanismes moléculaires de l'instabilité génomique — des états de crise induits par les télomères et du remodelage épigénétique aux sites de cassure jusqu'aux stratégies thérapeutiques de pointe ciblant la fidélité de la réparation de l'ADN dans le vieillissement et le cancer.
Découvrez ce qu'est réellement le DNA, comment des agressions du quotidien comme le soleil et le stress peuvent l'endommager, et pourquoi protéger votre code génétique est le secret d'une vie plus longue et en meilleure santé.
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
A Danish cohort of 49,894 adults shows first-time seizures carry a 76-fold elevated risk of neurological cancer and double the risk of non-neurological cancers within one year.
